ROLEC's Has Extended Its Range Of Premium Modular Suspension Arms For Industrial Controls/HMI
'ROLEC's suspension arm systems offer versatile, robust solutions for smart factories, ensuring optimal positioning of HMI and control equipment.' — Sean Bailey
BRIDGEVILLE, PA, UNITED STATES, March 24, 2025 / EINPresswire.com / -- The new range features profiPLUS 70 for payloads up to 120 kg, profiPLUS 50 for payloads up to 80 kg, and taraSMART for loads just over 40 kg.
These modular suspension arm systems – all rated IP 54 – are ideal for industrial electronics applications including HMI, process automation, machine control, IoT/IIoT and Industry 4.0/smart factory applications.
Each model offers a wide choice of couplings, adaptors, joints, elbows, bases and support profiles that enable designers to configure their ideal suspension arm quickly and easily. All three arms provide plenty of space for routing HDMI or DVI cables, or network plugs.
Robust profiPLUS 70 and profiPLUS 50 are recommended for use with ROLEC's advanced multiPANEL and profiPANEL HMI/panel enclosures. Patented 'one screw adjustment' speeds up installation.
Integrated cable protection safeguards the wiring inside. The profiPLUS 70 range includes an adapter for connecting it to profiPLUS 50, making it possible to mount display panels from leading manufacturers including Siemens, B&R and Beckhoff.
Versatile taraSMART is a simpler and more cost-effective arm based on tried and tested technology from the two profiPLUS ranges. It offers the choice of round (Ø48 mm) or rectangular support profiles.
All three ranges feature aluminum profiles in anodized silver. The diecast aluminum components are light gray (RAL 7035) with PVC-P bellows in anthracite (RAL 7016) and POM covers in slate gray (RAL 7015). The plastic covers for taraSMART's components are anthracite (RAL 7016).
. Services include CNC machining, custom colours, printing/engraving of legends and logo and assembly.
SEAN J BAILEY
+1 888-658-5774
Legal Disclaimer:
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
TransMedics Group Inc (TMDX) Q2 2025 Earnings Call Highlights: Record Revenue Growth and ...
Release Date: July 30, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points TransMedics Group Inc (NASDAQ:TMDX) reported a 38% year-over-year revenue growth for Q2 2025, reaching $157.4 million. The company achieved a new high water mark for clinical cases and revenue, demonstrating significant operating leverage. TransMedics Group Inc (NASDAQ:TMDX) maintained a steady gross margin of 61.4% in Q2 2025. The company added approximately $90 million to its balance sheet, ending Q2 with over $400 million in cash. TransMedics Group Inc (NASDAQ:TMDX) received FDA conditional approval for the OCS lung IDE and is on track to launch both heart and lung clinical programs before year-end. Negative Points There is market confusion and noise following comments made by a competitor in the organ preservation ecosystem. The company anticipates some minor and transient seasonality in Q3 performance due to summer vacation season. Operating expenses increased by 6% year over year, driven by a 50% increase in R&D expenses. The company faces potential challenges from the US National Transplant modernization initiative, which could impact smaller market players. There is ongoing concern about the impact of oversight on DCD usage, which could affect the company's operations. Q & A Highlights Warning! GuruFocus has detected 4 Warning Sign with TMDX. Q: Can you provide insights on the seasonality impact observed in July and how it compares to last year? A: We are seeing some signs of seasonality, similar to last year, but slightly less pronounced. However, it's still early in the quarter, and we expect some seasonality in Q3 due to various factors. Overall, the impact seems to be slightly less than last year, but it's too early to establish a trend. - Walid Hassanein, President and CEO Q: Are there any concerns about the impact of increased oversight on DCD usage following recent media coverage? A: We believe that some level of oversight could actually benefit the transplant market, especially in DCD. The lack of oversight has led to inefficiencies and lost opportunities for organ preservation. We are confident that our business model can operate effectively in both the current and any future systems. - Walid Hassanein, President and CEO Q: Were there any changes to the lung trial design after discussions with the FDA? A: The clinical trial design remains unchanged. Most of the remaining questions from the FDA are focused on pre-clinical testing. We plan to publish the full design of the clinical program on in late August or early September. - Walid Hassanein, President and CEO Q: What are your thoughts on the US heart market, given the recent flat trend in volumes? A: The heart market has experienced ebbs and flows due to waiting list dynamics. We expect the market to rebound, especially with the introduction of our next-gen heart technology. The growth of DCD and other factors may have temporarily impacted volumes, but we see this as a transient phenomenon. - Walid Hassanein, President and CEO Q: How do you see the NextGen OCS platform impacting lung transplants? A: The NextGen OCS platform is designed to address historical concerns in the US lung perfusion market, such as lung edema and perfusion limitations. We aim to prove the superiority of our platform over cold storage with level one evidence, potentially establishing it as the next standard of care. - Walid Hassanein, President and CEO For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
2 hours ago
- Business Wire
Sensorion Announces Its Participation In Upcoming Investor Conferences
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced its participation in upcoming investor conferences to be held in September and October 2025. Nawal Ouzren, Chief Executive Officer of Sensorion, and Laurene Danon, Chief Financial Officer, will attend the following events: 27th Annual H.C. Wainwright Global Investment Conference, to be held in New York City, USA, on September 8-10, 2025. Baird 2025 Global Healthcare Conference, to be held in New York City, USA, on September 9-10, 2025. European Midcap Event (CF&B), to be held at the Four Seasons Hôtel George V in Paris, France, on September 30 and October 1, 2025. Portzamparc Biotech & Health Seminar, taking place virtually on October 1-2, 2025. Chardan's 9 th Annual Genetic Medicines Conference, to be held in New York City, USA, on October 21, 2025. If you would like to meet members of Sensorion's management team at any of these events, please contact us by email at About Sensorion Sensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat, and prevent hearing loss disorders, a significant global unmet medical need. Sensorion has built a unique R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and mechanisms of action for drug candidates. It has two gene therapy programs aimed at correcting hereditary monogenic forms of deafness, developed in the framework of its broad strategic collaboration focused on the genetics of hearing with the Institut Pasteur. SENS-501 (OTOF-GT) currently being developed in a Phase 1/2 clinical trial, targets deafness caused by mutations of the gene encoding for otoferlin and GJB2-GT targets hearing loss related to mutations in GJB2 gene to potentially address important hearing loss segments in adults and children. The Company is also working on the identification of biomarkers to improve diagnosis of these underserved illnesses. Sensorion's portfolio also comprises programs of a clinical-stage small molecule, SENS-401 (Arazasetron), for the treatment and prevention of hearing loss disorders. Sensorion's small molecule progresses in a Phase 2 proof of concept clinical study of SENS-401 in Cisplatin-Induced Ototoxicity (CIO) for the preservation of residual hearing. Sensorion, with partner Cochlear Limited, completed in 2024 a Phase 2a study of SENS-401 for the residual hearing preservation in patients scheduled for cochlear implantation. A Phase 2 study of SENS-401 was also completed in Sudden Sensorineural Hearing Loss (SSNHL) in January 2022. Disclaimer This press release contains certain forward-looking statements concerning Sensorion and its business. Such forward looking statements are based on assumptions that Sensorion considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the 2024 full year report published on March 14, 2025, and available on our website and to the development of economic conditions, financial markets and the markets in which Sensorion operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Sensorion or not currently considered material by Sensorion. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Sensorion to be materially different from such forward-looking statements. This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Sensorion shares in any country. The communication of this press release in certain countries may constitute a violation of local laws and regulations. Any recipient of this press release must inform oneself of any such local restrictions and comply therewith.
Yahoo
7 hours ago
- Yahoo
AIG Women's British Open prize fund increased to $9.75 million for 2025
The purse for the AIG Women's British Open has tripled since before the R&A and AIG first partnered in 2019. The 2025 prize fund of $9.75 million is up $250,000 from last year. This year's champion will receive $1,462,500, which sets a new record for the 49-year-old championship. Here's a full breakdown showing the growth of the purse: • 2025 - $9.75 million• 2024 - $9.5 million• 2023 - $9 million• 2022 - $7.3 million• 2021 - $5.8 million• 2020 - $4.5 million• 2019 - $4.5 million (beginning of The R&A and AIG partnership)• 2018 - $3.25 million This year, the KPMG Women's PGA raised its purse to $12 million, matching the record set by the U.S. Women's Open. Both the Amundi Evian Championship and Chevron Championship featured purses of $8 million in 2025. AIG Women's Open 2025 prize money, payouts 1. $1,462,5002. 962,4243. 697,0594. 538,3135. 432,4936. 353,1207. 294,9158 257,8799. 231,42110. 210,25311. 194,37412. 181,14513. 169,50414. 158,92515. 149,39816. 140,93317. 133,53018. 127,17819. 121,88920. 117,65121. 113,42422. 109,18623. 104,95824. 100,72125. 97,01926. 93,31827. 89,60528. 85,90429. 82,20230. 79,02731. 75,85132. 72,67533. 69,49934. 66,32435. 63,68436. 61,03437. 58,39538. 55,74539. 53,09540. 50,98141. 48,86742. 46,75443. 44,63044. 42,51645. 40,92846. 39,34047. 37,75248. 36,16449. 34,57650. 32,98951. 31,93752. 30,87553. 29,81354. 28,76155. 27,69956. 26,63757. 25,58658. 24,52359. 23,47260. 22,41061. 21,88462. 21,34863. 20,82264. 20,29665. 19,76066. 19,23467. 18,70868. 18,17269. 17,64670. 17,12071. 12,77772. 12,48273. 12,18674. 11,89175. 11,59576. 11,300*Those who miss the cut will earn $4,250. This article originally appeared on Golfweek: AIG Women's British Open 2025: Prize fund increased to $9.75 million
